{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T01:16:58Z","timestamp":1746753418343,"version":"3.37.3"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A case of successful transition from high-dose epoprostenol to high-dose subcutaneous treprostinil for treatment of pulmonary arterial hypertension (PAH) is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>PAH is a chronically progressive disease characterized by pulmonary artery luminal narrowing that causes increased pulmonary artery pressures leading to right ventricular failure. Parenteral prostacyclin analogues, such as epoprostenol and treprostinil, are direct vasodilators and are cornerstones of therapy for patients with severe disease that have been proven to reduce mortality and increase exercise tolerance. These agents must be administered continuously via intravenous or subcutaneous devices and are high-risk medications due to their potent vasodilatory actions. Chronic use of these medications requires constant attention from both providers and patients because of potential complications including central venous catheter infection, thromboembolism, therapy interruptions, and other undesirable consequences. This case report describes management of a 35-year-old male patient on high-dose outpatient intravenous epoprostenol (101 ng\/kg\/min; dosing weight, 47 kg) for treatment of PAH who was admitted to the hospital with a malfunctioning central venous catheter. Surrounding manipulation of the central catheter, the patient experienced an ischemic stroke that led to cognitive disability resulting in a lack of ability to manage his previously used home infusion device. The patient was successfully transitioned from intravenous epoprostenol to subcutaneous treprostinil (discharge dose, 200 ng\/kg\/min) over 5 days by infusing both medications simultaneously and adjusting doses based upon patient-reported symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This successful transition from high-dose epoprostenol to high-dose subcutaneous treprostinil demonstrates the importance in considering patient-specific factors during high-risk medication transitions, the value of a patient-directed flexible prostacyclin transition plan, and the benefit of institutional training and education in ensuring the safe use of parenteral prostacyclin analogues.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae290","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:30:08Z","timestamp":1728502208000},"page":"e256-e261","source":"Crossref","is-referenced-by-count":1,"title":["Dual prostacyclin infusions: A case report of a patient symptom\u2013driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension"],"prefix":"10.1093","volume":"82","author":[{"given":"Jessica N","family":"Stone","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, The University of Kansas Health System , Kansas City, KS ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-1322","authenticated-orcid":false,"given":"Dalton J","family":"Kuebel","sequence":"additional","affiliation":[{"name":"UC Health \u2013 University of Cincinnati Medical Center Department of Pharmacy Services, , Cincinnati, OH"},{"name":"Division of Pharmacy Practice and Administrative Sciences, University of Cincinnati James L. Winkle College of Pharmacy , Cincinnati, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9641-3667","authenticated-orcid":false,"given":"Maria R","family":"Guido","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administrative Sciences, University of Cincinnati James L. Winkle College of Pharmacy , Cincinnati, OH"},{"name":"Pharmacy Administration, UC Health , Cincinnati, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-1707","authenticated-orcid":false,"given":"Jean M","family":"Elwing","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati , Cincinnati, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7109-2692","authenticated-orcid":false,"given":"Arun","family":"Jose","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati , Cincinnati, OH"},{"name":"Cincinnati VA Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"2025022017452685200_CIT0001","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N Engl J Med"},{"issue":"38","key":"2025022017452685200_CIT0002","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/euheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"2025022017452685200_CIT0003","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"issue":"4","key":"2025022017452685200_CIT0004","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jchf.2013.05.004","article-title":"Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension","volume":"1","author":"Brittain","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"5","key":"2025022017452685200_CIT0005","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"year":"2022","author":"Veletri (epoprostenol)","key":"2025022017452685200_CIT0006"},{"year":"2021","author":"Remodulin (treprostinil)","key":"2025022017452685200_CIT0007"},{"key":"2025022017452685200_CIT0008","doi-asserted-by":"publisher","first-page":"106649","DOI":"10.1016\/j.rmed.2021.106649","article-title":"Complications associated with peripherally inserted central catheters and Hickman in patients with advanced pulmonary hypertension treated with intravenous prostanoids","volume":"189","author":"Hinojosa","year":"2021","journal-title":"Respir Med"},{"issue":"1","key":"2025022017452685200_CIT0009","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"2025022017452685200_CIT0010","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2025022017452685200_CIT0011","doi-asserted-by":"publisher","first-page":"ytaa578","DOI":"10.1093\/ehjcr\/ytaa578","article-title":"Case report: stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension","volume":"5","author":"Mori","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"2025022017452685200_CIT0012","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2020.02.050","article-title":"Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension","volume":"306","author":"Mouratoglou","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025022017452685200_CIT0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2023.08.078","article-title":"Transition from Intravenous epoprostenol to treprostinil due to intolerable side effects in patients with pulmonary arterial hypertension","volume":"206","author":"Kikuchi","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae290\/60065273\/zxae290.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/5\/e256\/60065273\/zxae290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/5\/e256\/60065273\/zxae290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:45:37Z","timestamp":1740073537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/5\/e256\/7828168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,19]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae290","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,3,1]]},"published":{"date-parts":[[2024,10,19]]}}}